JAMA Intern Med:PCI联合药物治疗效果或不优于单纯药物治疗

2014-01-09 高晓方 译 医学论坛网

美国一项荟萃分析表明,在伴有客观心肌缺血的稳定性冠脉疾病患者中,与单纯药物治疗相比,经皮冠脉介入治疗(PCI)联合药物治疗与死亡、非致命性心梗、计划外血运重建和心绞痛减少无相关性。论文12月2日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。 研究者检索了Medline、Cochrane和PubMed数据库和相关未发表资料,并纳入在稳定性冠脉疾病患

美国一项荟萃分析表明,在伴有客观心肌缺血的稳定性冠脉疾病患者中,与单纯药物治疗相比,经皮冠脉介入治疗(PCI)联合药物治疗与死亡、非致命性心梗、计划外血运重建和心绞痛减少无相关性。论文12月2日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。【原文下载】

研究者检索了Medline、Cochrane和PubMed数据库和相关未发表资料,并纳入在稳定性冠脉疾病患者中对比PCI联合药物治疗以及单纯药物治疗的随机临床试验。在纳入试验中,应用支架和他汀类的患者需超过50%。转归分析包括全因死亡、非致命性心梗、计划外血运重建和心绞痛。利用随机效应模型计算汇总比值比(OR)。

结果显示,共有包括5286例患者的5项研究纳入纳入标准,其中4064例患者被诊断为心肌缺血。随访时间介入231天至5年之间(中位5年)。PCI联合药物治疗组和单纯药物治疗组的死亡率分别为6.5%和7.3%(OR 0.90),非致命性心梗发生率分别为9.2%和7.6%(OR 1.24),计划外血运重建率分别为18.3%和28.4%(OR 0.64),心绞痛发生率分别为20.3%和23.3%(OR 0.91)。

原文出处:

Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL.Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials.JAMA Intern Med. 2013 Dec 2. doi: 10.1001/jamainternmed.2013.12855. 【原文下载】


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893874, encodeId=5c4718938e47d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat Oct 25 18:39:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606089, encodeId=67971606089c4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 11 02:39:00 CST 2014, time=2014-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6746, encodeId=b51f6e4694, content=很多知识都受到质疑。尤其是PCI过用,有人为因素!PCI可以用,但应该慎用,应该选择药物疗效不佳人群,而不是一见狭窄就用, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jackxu, createdTime=Thu Jan 09 21:23:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6743, encodeId=b99d6e436c, content=再一次对稳定性心绞痛PCI治疗提出质疑。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=751564749, createdName=zhenggang, createdTime=Thu Jan 09 20:40:00 CST 2014, time=2014-01-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893874, encodeId=5c4718938e47d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat Oct 25 18:39:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606089, encodeId=67971606089c4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 11 02:39:00 CST 2014, time=2014-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6746, encodeId=b51f6e4694, content=很多知识都受到质疑。尤其是PCI过用,有人为因素!PCI可以用,但应该慎用,应该选择药物疗效不佳人群,而不是一见狭窄就用, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jackxu, createdTime=Thu Jan 09 21:23:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6743, encodeId=b99d6e436c, content=再一次对稳定性心绞痛PCI治疗提出质疑。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=751564749, createdName=zhenggang, createdTime=Thu Jan 09 20:40:00 CST 2014, time=2014-01-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893874, encodeId=5c4718938e47d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat Oct 25 18:39:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606089, encodeId=67971606089c4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 11 02:39:00 CST 2014, time=2014-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6746, encodeId=b51f6e4694, content=很多知识都受到质疑。尤其是PCI过用,有人为因素!PCI可以用,但应该慎用,应该选择药物疗效不佳人群,而不是一见狭窄就用, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jackxu, createdTime=Thu Jan 09 21:23:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6743, encodeId=b99d6e436c, content=再一次对稳定性心绞痛PCI治疗提出质疑。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=751564749, createdName=zhenggang, createdTime=Thu Jan 09 20:40:00 CST 2014, time=2014-01-09, status=1, ipAttribution=)]
    2014-01-09 jackxu

    很多知识都受到质疑。尤其是PCI过用,有人为因素!PCI可以用,但应该慎用,应该选择药物疗效不佳人群,而不是一见狭窄就用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1893874, encodeId=5c4718938e47d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat Oct 25 18:39:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606089, encodeId=67971606089c4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 11 02:39:00 CST 2014, time=2014-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6746, encodeId=b51f6e4694, content=很多知识都受到质疑。尤其是PCI过用,有人为因素!PCI可以用,但应该慎用,应该选择药物疗效不佳人群,而不是一见狭窄就用, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jackxu, createdTime=Thu Jan 09 21:23:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6743, encodeId=b99d6e436c, content=再一次对稳定性心绞痛PCI治疗提出质疑。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=751564749, createdName=zhenggang, createdTime=Thu Jan 09 20:40:00 CST 2014, time=2014-01-09, status=1, ipAttribution=)]
    2014-01-09 zhenggang

    再一次对稳定性心绞痛PCI治疗提出质疑。

    0